Evidence map›Paper›PMID 33822361›Full record

Trial reportJournal of medical virology2021

Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: A randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms.

Renuka Ananth Kalyan Kadali, Ravali Janagama, Sharanya Peruru, Viswanath Gajula, Rajasekhar R Madathala, Nikhita Chennaiahgari, Srikrishna V Malayala

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 6 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 6 syntheses or guidelines pooled it, 145 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Renuka Ananth Kalyan KadaliDepartment of Internal Medicine, Harnett Health System, Affiliated with Cape Fear Valley Health System, Lillington, North Carolina, USA.ORCID https://orcid.org/0000-0003-4105-7743
Ravali JanagamaKidzcare Pediatrics, Sanford, North Carolina, USA.ORCID https://orcid.org/0000-0002-7601-7648
Sharanya PeruruDepartment of Statistics, North Carolina State University, Raleigh, North Carolina, USA.
Viswanath GajulaDepartment of Pediatrics, Division of Pediatric Critical Care Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Rajasekhar R MadathalaDepartment of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Nikhita ChennaiahgariDepartment of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Srikrishna V MalayalaDepartment of Internal Medicine, Temple University Hospital, Philadelphia, Pennsylvania, USA.
Mayo Clinic · USCampbell University · USNorth Carolina State University · USTemple University Hospital · USUniversity of Mississippi Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are concerns regarding the side effects of the new coronavirus disease 2019 (COVID-19) mRNA-1273 vaccine among healthcare workers (HCWs) in the United States. The objective of the study was to investigate the side effects of the mRNA-1273 vaccine with detailed review of organ systems. A randomized, cross-sectional study using an independent online survey questionnaire was conducted to collect responses from HCWs. Of all participants, 87.8% (1116/1271) provided complete responses. Of them, 38.7% (432/1116) received the mRNA-1273 vaccine, among which, 89.35% were females; 425 of these 432 mRNA-1273 vaccine recipients (98.34%) reported at least one or more symptoms. The results were classified based on the frequency of symptoms reported postvaccination. Of these, 254/432 (58.8%) were able to continue their daily routine activities. 108/432 (25%) temporarily had trouble to perform daily activities, 120/432 (27.78%) required transient time off from work, 17/432 (3.94%) required help from an outpatient provider, 1/432 (0.23%) required help from emergency department, and none of them were hospitalized. Despite the wide array of self-reported symptoms, 97.02% of the HCWs did not intend to skip the second dose of vaccine. Among all the symptoms reported, localized pain, generalized weakness, headache, myalgia, chills, fever, nausea, joint pains, sweating, localized swelling at the injection site, dizziness, itching, rash, decreased appetite, muscle spasm, decreased sleep quality, and brain fogging were the most commonly reported symptoms (in descending order of occurrence). Most of the symptoms reported were nonlife threatening. Despite the wide array of self-reported symptoms, there appears to be a higher acceptance for this vaccine.

Indexed as

2019-nCoV Vaccine mRNA-1273Activities of Daily LivingAdultAgedAnaphylaxisCOVID-19COVID-19 VaccinesCross-Sectional StudiesFemaleFeverHealth PersonnelHumansInjection Site ReactionMaleMiddle AgedSARS-CoV-22019-nCoV Vaccine mRNA-1273COVID-19 Vaccinesadverse eventsCOVIDCOVID-19ModernamRNA-1273SARS-CoV-2side effectssymptomsvaccine

Identifiers

PMID33822361
PMCPMC8250701
OpenAlexW3143941795

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.